PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Capivasertib→

Capivasertib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1143532-39-1
Molecular formula
C21H25ClN6O2
Molecular weight
428.9 g/mol
Drug class
ATP-competitive pan-AKT kinase inhibitortargeted antineoplastic
Mechanism of action
Inhibits all three AKT isoforms (AKT1, AKT2 and AKT3), reducing signalling through the PI3K/AKT pathway and downstream pathways involved in tumour-cell growth and survival.
Indications / reported uses
  • In combination with fulvestrant for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations detected by an FDA-authorised test after progression on or recurrence following endocrine-based therapy
  • In combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer under the US FDA indication approved June 12 2026

Sources: US DailyMed — TRUQAP label, updated September 16 2026 · US FDA — Capivasertib approval for PTEN-deficient prostate cancer, June 12 2026 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Capivasertib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Capivasertib Permitted Daily Exposure (PDE) report (the Capivasertib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Capivasertib Occupational Exposure Limit (OEL) report (the Capivasertib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.